Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ

Bladder Cancer Clinical Trial

Official title:

Phase II Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Patients With Non-Invasive Urothelial Carcinoma in Situ (CIS) Previously Treated With Bacille Calmette-Guérin (BCG)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00462488
• Other study ID #: VB4-845-02-IIA
• Status: Completed
• Phase: Phase 2
• Start date: March 2007
• Est. completion date: October 2009

Study information

• Verified date: April 2020
• Source: Viventia Bio
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and tolerability of Vicinium when administered as a monotherapy intravesical instillation in patients with non-invasive urothelial carcinoma in situ (CIS) who failed previous treatment with Bacille Calmette Guérin (BCG).

Description:

A phase II study was performed to assess the efficacy and tolerability of intravesical Vicinium in patients with urothelial carcinoma in situ of the bladder. Bacillus Calmette-Guérin treatment had previously failed in all patients. A total of 46 patients were treated with Vicinium with half being administered 30mg/dose once per week for 6 weeks (cohort 1) and the other half (cohort 2) the same dose but administered once per week for 12 consecutive weeks. Disease assessments consisting of urine cytology, cystoscopy and, if indicated, biopsy were performed at 3 month intervals. Patients that were disease-free at the assessment time point were allowed to continue treatment in the maintenance phase which consisted of three weekly doses, followed by 9 weeks of no treatment. As long as the patient remained disease-free, treatment continued for a total of one year.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: October 2009
• Est. primary completion date: October 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Disease Characteristics

• The patient must be male or female 18 years of age or older.

• The patient must have histologically-confirmed Transitional Cell Carcinoma (TCC) of the bladder.

• The patient must have histologically-confirmed carcinoma in situ (CIS), with or without non-invasive papillary disease

• The patient must have immunohistochemically-confirmed EpCAM positive disease.

• The patient must have a life expectancy of at least 12 months.

Prior/Concurrent Therapy

• The patient must have, within the last 24 months, failed to respond to at least 1 cycle of treatment with BCG (with or without interferon) or be intolerant to BCG treatment.

• The patient must have had a transurethral resection of the bladder tumour (TURBT) mapping the location of tumour and quantifying the area of bladder affected.

• The patient must have documented residual CIS (i.e. unresectable disease) prior to study drug administration.

Patient Characteristics

The patient must have adequate organ function, as defined by the clinical trial protocol

Other

• The patient must have the ability to understand and sign an Independent Ethics Committee or Institutional Review Board (IEC/IRB)- approved informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment and is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

• The patient has evidence of urethral or upper tract transitional cell carcinoma (TCC) by biopsy or upper tract radiological imaging (i.e. intravenous pyelogram, computed tomography (CT) urogram, or retrograde pyelogram) within the past 2 years

• The patient has hydronephrosis

• The patient has had prior intravesical chemotherapy or investigational or anti-cancer treatments within the last 2 months, inclusive of single-dose adjuvant intravesical chemotherapy immediately post-TURBT

• The patient has existing severe urinary tract infection or recurrent severe bacterial cystitis

• The patient has active, uncontrolled impairment of the renal, hepatobiliary, cardiovascular, gastrointestinal, urogenital, neurologic or hematopoietic systems which, in the opinion of the investigator, would predispose the patient to the development of complications from the administration of intravesical therapy and/or general anesthesia

• Any patient who, in the opinion of the investigator, cannot tolerate intravesical administration or intravesical surgical manipulation (cystoscopy, biopsy) due to the presence of concomitant serious illness (i.e. uncontrolled cardiac or respiratory disorders)

• The patient is pregnant or breast feeding

• Women of reproductive age (who are not either medically or surgically incapable or bearing children) and all men may not participate unless agreeing to use double barrier contraception, or commit to abstinence during the period of therapy

Related Conditions & MeSH terms

• Bladder Cancer
• Bladder Neoplasms
• Bladder Tumors
• Carcinoma in Situ
• Carcinoma, Transitional Cell
• Urinary Bladder Cancer
• Urinary Bladder Neoplasms

Intervention

Drug:
• Vicinium
Intravesical administration of Vicinium

Locations

Country	Name	City	State
Canada	The Male/Female Health and Research Centre, Royal Court Medical Centre	Barrie	Ontario
Canada	Urology Resource Centre	Burlington	Ontario
Canada	McMaster University, Institute of Urology at Saint Joseph's Hospital	Hamilton	Ontario
Canada	Centre for Applied Urological Research	Kingston	Ontario
Canada	London Health Sciences Centre	London	Ontario
Canada	The Fe/Male Health Centre	Oakville	Ontario
Canada	Todd Webster, M.D.	Owen Sound	Ontario
Canada	The Scarborough Hospital	Scarborough	Ontario
Canada	Centre Hospitalier Universitaire de Sherbrooke, Hopital Fleuimont	Sherbrooke	Quebec
Canada	Andreou Research	Surrey	British Columbia
Canada	Princess Margaret Hospital	Toronto	Ontario
Canada	University of Toronto, Sunnybrook Health Sciences Centre	Toronto	Ontario
Canada	Can-Med Clinical Research Inc.	Victoria	British Columbia
United States	Johns Hopkins Medical Institutions	Baltimore	Maryland
United States	Corpus Christi Urology Group, LLP	Corpus Christi	Texas
United States	Duke University Medical Center	Durham	North Carolina
United States	Lawrenceville Urology	Lawrenceville	New Jersey
United States	Grand Strand Urology	Myrtle Beach	South Carolina
United States	Urology of Virginia	Newport News	Virginia
United States	Oregon Urology Institute Research	Springfield	Oregon
United States	Southeastern Research Group, Inc.	Tallahassee	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Viventia Bio

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment Schedule A: 12-Week Efficacy, Treatment Schedule B: 13-Week Efficacy	Complete response rate in subjects with carcinoma in situ (CIS) non-muscle invasive bladder cancer (NMIBC) following the induction phase (3-month evaluation point) of Vicinium treatment	12 or 13 weeks